Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02290340 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 151
- Enrollment target
NCT02290340 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 151 participants.
The verdict
NCT02290340, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 151 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of an extended half-life anti-respiratory syncytial virus (RSV) monoclonal antibody compared to placebo when administered to healthy preterm infants.
Interventions
- DRUG Placebo
- DRUG MEDI8897 10 mg
- DRUG MEDI8897 25 mg
- DRUG MEDI8897 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2015-01-13 |
| Est. Completion | 2016-09-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02290340
The ClinicalTrials.gov registry entry for NCT02290340 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02290340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02290340 about?
NCT02290340 is a clinical study titled "A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants". The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of an extended half-life anti-respiratory syncytial virus (RSV) monoclonal antibody compared to placebo when administered to healthy preterm infants.
What is the current status of trial NCT02290340?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 151 participants. The study started on 2015-01-13. Estimated completion is 2016-09-28.
What interventions are being tested in trial NCT02290340?
The interventions under investigation include: Placebo (DRUG), MEDI8897 10 mg (DRUG), MEDI8897 25 mg (DRUG), MEDI8897 50 mg (DRUG).
Who is sponsoring clinical trial NCT02290340?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.